Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  title={Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.},
  author={Robert G Maki and David R. D'Adamo and Mary Louise Keohan and Michael F Saulle and Scott M. Schuetze and Samir D. Undevia and Michael B Livingston and Matthew M. Cooney and Martee L. Hensley and Monica M. Mita and Chris H M Takimoto and Andrew S. Kraft and Anthony D Elias and Bruce B. Brockstein and Nathalie E. Blach{\`e}re and Mark A. Edgar and Lawrence H. Schwartz and L Qin and Cristina R Antonescu and Gary K. Schwartz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={27 19},
PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma. PATIENTS AND METHODS We employed a multiarm study design, each representing a sarcoma subtype with its own Simon optimal two-stage design. In each arm, 12 patients who received 0 to 1 prior lines of therapy were treated (0 to 3 for angiosarcoma and malignant peripheral-nerve sheath tumor). If… CONTINUE READING